Oxford BioMedica (LON:OXB) Reaches New 1-Year Low at $552.00

Oxford BioMedica plc (LON:OXB) shares hit a new 52-week low on Thursday . The company traded as low as GBX 552 ($7.21) and last traded at GBX 552 ($7.21), with a volume of 125559 shares trading hands. The stock had previously closed at GBX 601 ($7.85).

A number of equities analysts have weighed in on OXB shares. Peel Hunt reiterated a “buy” rating on shares of Oxford BioMedica in a report on Monday, September 2nd. Peel Hunt reiterated a “buy” rating on shares of Oxford BioMedica in a report on Wednesday, June 26th.

The company has a debt-to-equity ratio of 10.55, a quick ratio of 1.80 and a current ratio of 2.21. The firm has a market cap of $423.76 million and a price-to-earnings ratio of -47.59. The company’s fifty day moving average is GBX 657.52 and its two-hundred day moving average is GBX 689.11.

In other Oxford BioMedica news, insider Lorenzo Tallarigo bought 368 shares of Oxford BioMedica stock in a transaction that occurred on Thursday, July 25th. The shares were acquired at an average price of GBX 730 ($9.54) per share, for a total transaction of £2,686.40 ($3,510.26). Insiders have purchased a total of 1,165 shares of company stock worth $803,082 in the last 90 days.

About Oxford BioMedica (LON:OXB)

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Featured Story: What are the benefits of a portfolio tracker?

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.